A detailed history of Raleigh Capital Management Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 65 shares of MRNA stock, worth $2,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65
Previous 156 58.33%
Holding current value
$2,560
Previous $18,000 77.78%
% of portfolio
0.0%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$63.64 - $125.14 $5,791 - $11,387
-91 Reduced 58.33%
65 $4,000
Q2 2024

Jul 31, 2024

BUY
$101.21 - $166.61 $4,048 - $6,664
40 Added 34.48%
156 $18,000
Q1 2024

May 13, 2024

BUY
$85.37 - $115.44 $6,914 - $9,350
81 Added 231.43%
116 $12,000
Q4 2023

Feb 21, 2024

BUY
$69.51 - $104.43 $2,432 - $3,655
35 New
35 $3,000
Q1 2022

May 12, 2022

SELL
$126.46 - $235.05 $252 - $470
-2 Closed
0 $0
Q4 2021

Feb 16, 2022

BUY
$225.82 - $368.51 $451 - $737
2 New
2 $1,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Raleigh Capital Management Inc. Portfolio

Follow Raleigh Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.